Headlines about AxoGen (NASDAQ:AXGN) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.1570460262003 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- BidaskClub Upgrades AxoGen (AXGN) to “Strong-Buy” (americanbankingnews.com)
- Zacks: Brokerages Expect AxoGen, Inc. (AXGN) Will Announce Earnings of -$0.09 Per Share (americanbankingnews.com)
- AxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 63,395 Shares (americanbankingnews.com)
- Financial Survey: AxoGen (AXGN) vs. Zynex (ZYXI) (americanbankingnews.com)
- AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference (finance.yahoo.com)
A number of research firms have weighed in on AXGN. Cantor Fitzgerald set a $37.00 target price on shares of AxoGen and gave the stock a “buy” rating in a report on Monday, January 8th. Jefferies Group began coverage on shares of AxoGen in a report on Thursday, November 30th. They set a “buy” rating and a $35.00 target price on the stock. William Blair began coverage on shares of AxoGen in a report on Monday, February 5th. They set an “outperform” rating on the stock. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Wedbush reaffirmed a “buy” rating and issued a $27.00 price objective (up from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $29.33.
Shares of AxoGen (NASDAQ:AXGN) opened at $28.95 on Friday. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95. AxoGen has a 12 month low of $9.55 and a 12 month high of $31.70. The company has a market cap of $987.02, a price-to-earnings ratio of -72.38 and a beta of 0.12.
In other news, CFO Jamie Mark Grooms sold 95,712 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $26.84, for a total value of $2,568,910.08. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders sold 313,397 shares of company stock worth $8,386,910. Insiders own 9.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://transcriptdaily.com/2018/02/25/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-axogen-axgn-share-price.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.